News Biosergen AB

Equities

BIOSGN

SE0016013460

Market Closed - Nasdaq Stockholm Other stock markets 15:17:26 02/05/2024 BST			5-day change	1st Jan Change
0.334 ^SEK	+1.21%		-13.70%	-62.05%

04-09	Biosergen to Issue New Units as Compensation Under Rights Issue	MT
03-27	Biosergen Raises SEK26.4 Million via Rights Issue	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Conversion of paid subscribed units and first day of trading with warrants of series TO3	04-16	AQ
Biosergen to Issue New Units as Compensation Under Rights Issue	04-09	MT
Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue	04-09	AQ
Biosergen Raises SEK26.4 Million via Rights Issue	03-27	MT
Biosergen announces the outcome in the rights issue	03-26	AQ
BioStock Investor Pitch: Biosergen	03-18	AQ
Members of the board of directors and management subscribe in ongoing rights issue	03-15	AQ
Research update Biosergen: Rights issue to fund crucial step for lead project	03-13	AQ
BioStock: Rights issue to give Biosergen first in-human efficacy data	03-12	AQ
BioStock: Biosergen attacks invisible threat of fungal infections	03-08	AQ
Carlsquare Equity Research interview with Biosergen	03-07	AQ
Biosergen CEO to BioStock: "Positive data give us a strong value proposition"	03-07	AQ
Biosergen publishes prospectus due to rights issue of units	03-05	AQ
Bulletin from the extraordinary general meeting in Biosergen AB (publ)	03-01	AQ
Biosergen publishes interim report for fourth quarter 2023	02-29	AQ
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	02-12	MT
Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.	02-12	AQ
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	02-12	CI
Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step	02-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biosergen AB

Equities

BIOSGN

SE0016013460

Summary

Filters